These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 19616331)

  • 1. The deletion mutant EGFRvIII significantly contributes to stress resistance typical for the tumour microenvironment.
    Theys J; Jutten B; Dubois L; Rouschop KM; Chiu RK; Li Y; Paesmans K; Lambin P; Lammering G; Wouters BG
    Radiother Oncol; 2009 Sep; 92(3):399-404. PubMed ID: 19616331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
    Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
    Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity.
    Lammering G; Hewit TH; Holmes M; Valerie K; Hawkins W; Lin PS; Mikkelsen RB; Schmidt-Ullrich RK
    Clin Cancer Res; 2004 Oct; 10(19):6732-43. PubMed ID: 15475464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.
    Mishima K; Johns TG; Luwor RB; Scott AM; Stockert E; Jungbluth AA; Ji XD; Suvarna P; Voland JR; Old LJ; Huang HJ; Cavenee WK
    Cancer Res; 2001 Jul; 61(14):5349-54. PubMed ID: 11454673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy.
    Blehm KN; Spiess PE; Bondaruk JE; Dujka ME; Villares GJ; Zhao YJ; Bogler O; Aldape KD; Grossman HB; Adam L; McConkey DJ; Czerniak BA; Dinney CP; Bar-Eli M
    Clin Cancer Res; 2006 Aug; 12(15):4671-7. PubMed ID: 16899617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer.
    Tang CK; Gong XQ; Moscatello DK; Wong AJ; Lippman ME
    Cancer Res; 2000 Jun; 60(11):3081-7. PubMed ID: 10850460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.
    Ramnarain DB; Park S; Lee DY; Hatanpaa KJ; Scoggin SO; Otu H; Libermann TA; Raisanen JM; Ashfaq R; Wong ET; Wu J; Elliott R; Habib AA
    Cancer Res; 2006 Jan; 66(2):867-74. PubMed ID: 16424019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of collapsin response mediator Protein1, as detected by iTRAQ analysis, promotes invasion of human gliomas expressing mutant EGFRvIII.
    Mukherjee J; DeSouza LV; Micallef J; Karim Z; Croul S; Siu KW; Guha A
    Cancer Res; 2009 Nov; 69(22):8545-54. PubMed ID: 19903856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of EGFR variant vIII promotes both radiation resistance and hypoxia tolerance.
    Weppler SA; Li Y; Dubois L; Lieuwes N; Jutten B; Lambin P; Wouters BG; Lammering G
    Radiother Oncol; 2007 Jun; 83(3):333-9. PubMed ID: 17512071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding of cetuximab to the EGFRvIII deletion mutant and its biological consequences in malignant glioma cells.
    Jutten B; Dubois L; Li Y; Aerts H; Wouters BG; Lambin P; Theys J; Lammering G
    Radiother Oncol; 2009 Sep; 92(3):393-8. PubMed ID: 19616334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.
    Shinojima N; Tada K; Shiraishi S; Kamiryo T; Kochi M; Nakamura H; Makino K; Saya H; Hirano H; Kuratsu J; Oka K; Ishimaru Y; Ushio Y
    Cancer Res; 2003 Oct; 63(20):6962-70. PubMed ID: 14583498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glioblastoma stem-like cell lines with either maintenance or loss of high-level EGFR amplification, generated via modulation of ligand concentration.
    Schulte A; Günther HS; Martens T; Zapf S; Riethdorf S; Wülfing C; Stoupiec M; Westphal M; Lamszus K
    Clin Cancer Res; 2012 Apr; 18(7):1901-13. PubMed ID: 22316604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiation-induced activation of a common variant of EGFR confers enhanced radioresistance.
    Lammering G; Valerie K; Lin PS; Hewit TH; Schmidt-Ullrich RK
    Radiother Oncol; 2004 Sep; 72(3):267-73. PubMed ID: 15450724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of Epidermal Growth Factor Receptor variant III in laryngeal carcinoma tissues.
    Yang B; Chen J; Zhang X; Cao J
    Auris Nasus Larynx; 2009 Dec; 36(6):682-7. PubMed ID: 19427146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. c-Myc is required for transformation of FDC-P1 cells by EGFRvIII.
    Rath O; Himmler A; Baum A; Sommergruber W; Beug H; Metz T
    FEBS Lett; 2007 May; 581(13):2549-56. PubMed ID: 17499721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas.
    Wikstrand CJ; Hale LP; Batra SK; Hill ML; Humphrey PA; Kurpad SN; McLendon RE; Moscatello D; Pegram CN; Reist CJ
    Cancer Res; 1995 Jul; 55(14):3140-8. PubMed ID: 7606735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The EGFRvIII variant in glioblastoma multiforme.
    Gan HK; Kaye AH; Luwor RB
    J Clin Neurosci; 2009 Jun; 16(6):748-54. PubMed ID: 19324552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance of EGFR and EGFRvIII expressions in an in vivo and in vitro model of human glioblastoma multiforme.
    Stockhausen MT; Broholm H; Villingshøj M; Kirchhoff M; Gerdes T; Kristoffersen K; Kosteljanetz M; Spang-Thomsen M; Poulsen HS
    Exp Cell Res; 2011 Jul; 317(11):1513-26. PubMed ID: 21514294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.
    Luwor RB; Johns TG; Murone C; Huang HJ; Cavenee WK; Ritter G; Old LJ; Burgess AW; Scott AM
    Cancer Res; 2001 Jul; 61(14):5355-61. PubMed ID: 11454674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deficient carbonic anhydrase 9 expression in UPR-impaired cells is associated with reduced survival in an acidic microenvironment.
    van den Beucken T; Ramaekers CH; Rouschop K; Koritzinsky M; Wouters BG
    Radiother Oncol; 2009 Sep; 92(3):437-42. PubMed ID: 19615771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.